AU1743997A - Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence - Google Patents
Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescenceInfo
- Publication number
- AU1743997A AU1743997A AU17439/97A AU1743997A AU1743997A AU 1743997 A AU1743997 A AU 1743997A AU 17439/97 A AU17439/97 A AU 17439/97A AU 1743997 A AU1743997 A AU 1743997A AU 1743997 A AU1743997 A AU 1743997A
- Authority
- AU
- Australia
- Prior art keywords
- adp
- ribose
- poly
- diseases associated
- treat diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1996/020630 WO1998027975A1 (en) | 1996-12-20 | 1996-12-20 | Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU1743997A true AU1743997A (en) | 1998-07-17 |
Family
ID=22256352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU17439/97A Abandoned AU1743997A (en) | 1996-12-20 | 1996-12-20 | Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU1743997A (en) |
| WO (1) | WO1998027975A1 (en) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5912225A (en) | 1997-04-14 | 1999-06-15 | Johns Hopkins Univ. School Of Medicine | Biodegradable poly (phosphoester-co-desaminotyrosyl L-tyrosine ester) compounds, compositions, articles and methods for making and using the same |
| US6291425B1 (en) | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| US7410995B1 (en) | 1998-08-14 | 2008-08-12 | Gpi Nil Holdings Inc. | N-linked sulfonamide of heterocyclic thioesters for vision and memory disorders |
| US7265150B1 (en) | 1998-08-14 | 2007-09-04 | Gpi Nil Holdings Inc. | Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds for vision and memory disorders |
| US7338976B1 (en) | 1998-08-14 | 2008-03-04 | Gpi Nil Holdings, Inc. | Heterocyclic esters or amides for vision and memory disorders |
| AU2001264595A1 (en) * | 2000-05-19 | 2001-12-03 | Guilford Pharmaceuticals Inc. | Sulfonamide and carbamide derivatives of 6(5h)phenanthridinones and their uses |
| AU2001273099A1 (en) * | 2000-07-13 | 2002-01-30 | Guilford Pharmaceuticals Inc. | Substituted 4,9-dihydrocyclopenta(imn) phenanthridine-5-ones, derivatives thereof and their uses |
| AU2002215737A1 (en) * | 2000-12-05 | 2002-06-18 | Chemokine Therapeutics Corporation | Tricyclic therapeutics for chemokine mediated diseases |
| CA2330350A1 (en) | 2000-12-05 | 2002-06-05 | Chemokine Therapeutics Corporation | Therapeutics for chemokine mediated diseases |
| RU2205009C1 (en) * | 2002-03-27 | 2003-05-27 | Государственный научный центр - Институт биофизики | Antiemetic agent benzamide |
| WO2012125521A1 (en) * | 2011-03-14 | 2012-09-20 | Eternity Bioscience Inc. | Quinazolinediones and their use |
| TWI527800B (en) | 2011-04-01 | 2016-04-01 | 南京英派藥業有限公司 | 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof |
| CN111655253A (en) | 2018-01-09 | 2020-09-11 | 杨百翰大学 | Compositions and methods for treating pain with wogonin |
| EP4143196A4 (en) | 2020-04-29 | 2024-04-17 | Relay Therapeutics, Inc. | PI3K-A INHIBITORS AND METHODS OF USE THEREOF |
| WO2023060262A1 (en) * | 2021-10-07 | 2023-04-13 | Relay Therapeutics, Inc. | Pi3k-alpha inhibitors and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5041653A (en) * | 1985-05-03 | 1991-08-20 | Sri International | Substituted benzamide radiosensitizers |
| WO1986006628A1 (en) * | 1985-05-03 | 1986-11-20 | Sri International | Benzamide and nicotinamide radiosensitizers |
| US5215738A (en) * | 1985-05-03 | 1993-06-01 | Sri International | Benzamide and nicotinamide radiosensitizers |
| US5032617A (en) * | 1985-05-03 | 1991-07-16 | Sri International | Substituted benzamide radiosensitizers |
| GB2244704B (en) * | 1990-05-04 | 1995-05-17 | Consultants Suppliers Limited | Substituted benzene compounds |
| GB9011833D0 (en) * | 1990-05-25 | 1990-07-18 | Collins Mary K L | Inhibition of viral infection |
| GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
-
1996
- 1996-12-20 WO PCT/US1996/020630 patent/WO1998027975A1/en active Application Filing
- 1996-12-20 AU AU17439/97A patent/AU1743997A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998027975A1 (en) | 1998-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU5774200A (en) | Intelligent splitter, system, and methods of use | |
| AU4520697A (en) | Use of substituted benzazoles as UV absorbers, new benzazoles and processes for their preparation | |
| AU1363797A (en) | Pixelated puzzle | |
| AU2905997A (en) | Quinoline sulfonamides as tnf inhibitors and as pde-iv inhibitors | |
| AU4308397A (en) | Substituted 2-pyrimidineamines, their preparation and their use as proteine kinase inhibitors | |
| AU3033097A (en) | Skin wash composition | |
| AU1743997A (en) | Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence | |
| AU2379001A (en) | Method and receiver for reducing the effect of multipath propagation | |
| AU3480297A (en) | Modified mcm-56, its preparation and use | |
| IL109963A0 (en) | E2-f1 enzyme and methods for the isolation, purification and use thereof | |
| AU3607497A (en) | CDMA communication system | |
| AU3534397A (en) | Improved dummy block construction | |
| AU2271097A (en) | High-power ampliflier using parallel transistors | |
| AU5652698A (en) | (2,3-dihydrobenzofuranyl)-thiazoles as phosphodiesterase inhibitors | |
| AU1475897A (en) | Cellular structure | |
| WO2000063247A3 (en) | Osteopontin-derived chemotactic and inhibitory agents and uses therefor | |
| AU1311297A (en) | Quinolin-2-(1H)-ones | |
| AU4685799A (en) | Telomerase inhibitors | |
| AU4501199A (en) | 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors | |
| AU5920399A (en) | Persistent diatomaceous earth molluskicidial composition | |
| AU1013997A (en) | Amylase inhibitors | |
| AU1451200A (en) | Dual reporter system and methods of use therefor | |
| GB2343844A8 (en) | Topical therapeutic composition comprising an enzyme | |
| AU3454797A (en) | Non-slip bandage | |
| AU4334297A (en) | Antiviral treatment |